CompletedPhase 2NCT06528457
Study to Examine the Effects of Oral Fenretinide
Studying Dengue fever
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Island Pharmaceuticals
- Principal Investigator
- Bert Slade, MD, MDCCRS
- Intervention
- ISLA101(drug)
- Enrollment
- 15 enrolled
- Eligibility
- 18-55 years · All sexes
- Timeline
- 2024 – 2025
Study locations (1)
- SUNY Upstate Medical University, East Syracuse, New York, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06528457 on ClinicalTrials.govOther trials for Dengue fever
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT06891950Butantan-DV Vaccine in Elderly Populations (DEN-04-IB)Butantan Institute
- RECRUITINGNANCT07412483A Controlled Human Infection Model of DengueTan Tock Seng Hospital
- RECRUITINGPHASE3NCT06579755A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years)Takeda
- RECRUITINGNCT07409857International Registry of Dengue Infection in Congenital Bleeding Disorders (DengueCBDR)Mahidol University
- ACTIVE NOT RECRUITINGPHASE3NCT07047521A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy AdultsTakeda
- ENROLLING BY INVITATIONPHASE2NCT07172100To Assess the Efficacy of Carica Papaya Leaf Extract in Improving Platelet Counts Among Pediatric Patients With Dengue-associated ThrombocytopeniaZiauddin Hospital
- RECRUITINGPHASE2NCT06551844Adaptive Dengue Antiviral Platform TrialOxford University Clinical Research Unit, Vietnam
- RECRUITINGNCT07007585Risk Factors for Hospitalization and Transfusion Criteria in Patients With Dengue Virus InfectionJose Ivan Rodriguez de Molina Serrano